Antares Pharma (ATRS) QuickShot Auto Injector Positive Data,

Antares Pharma Inc. (ATRS)

Male hypogonadism is a condition in which the body doesn't produce enough testosterone — the hormone that plays a key role in masculine growth and development during puberty — or has an impaired ability to produce sperm or both.

Hypogonadism in men causes a constellation of signs and symptoms that may include decreased libido, erectile dysfunction, decreased volume of ejaculate, loss of body and facial hair, weakness, decreased bone density, decreased lean body mass, increased body fat, fatigue and anaemia.

The prevalence of hypogonadism (low testosterone) increases with age. Researchers have found that the incidence of low testosterone increases from approximately 20% of men over 60, to 30% of men over 70 and 50% of men over 80 years of age.

Hypogonadism in adult men is often overlooked, even in the presence of associated symptoms, because hypogonadal men often ignore their symptoms or attribute them to alternate causes, including ageing

ATRS reported positive results from a multi-center phase 2 clinical study evaluating the pharmacokinetic profile of testosterone enanthate administered once-weekly by subcutaneous injection at doses of 50 mg and 100 mg using the VIBEX QuickShot auto injector in testosterone deficient adult males.

According to ATRS , the administration of testosterone using the company's proprietary QuickShot device showed that normal testosterone levels can be rapidly restored and then reliably maintained with reduced peak to trough fluctuations relative to those associated with intramuscular injections.

Unlike topical treatments for males with hypogonadism, currently approved injectable forms of testosterone do not carry a black box warning for risk of transference, which has been reported to lead to abnormal development of male sexual characteristics in women and children

ATRS ' VIBEX QuickShot auto injector emphasizes enhanced performance on the attributes contributing most to patients successfully controlling their testosterone deficiency – reliable and consistent blood levels, ease and speed of self-administration, comfort and discretion.

According to published data, 2013 U.S. sales of testosterone replacement therapies were approximately $2.8 billion dollars with prescriptions on average growing more than 20% annually.

ATRS focuses on self-administered parenteral pharmaceutical products and topical gel-based medicines.

More about Antares Pharma Inc. (ATRS) at www.antarespharma.com

**

Crown Equity Holdings Inc. (CRWE)

CRWE is currently developing its CRWE Network ( CRWE-PR.com ), a social networking service compatible with both, the mobile and desktop web platform, that is designed to target all the communities in the U.S. and Canada, which business model is based on selling advertising to local businesses.

CRWE-PR has included in its platform a coupon page, giving business owners some flexibility in instantly creating, modifying and publishing promotional deals to consumers of every kind, such as local restaurants, auto repairs, realtors, bars, movie theaters, retailers, golf courses, auto dealerships and any other variety of businesses existing within a community.

CRWE presently has more than 50 cities in its network of community publications.

CRWE Network’s goal is to facilitate exchanges of goods and services in a manner similar to Craigslist, a classified advertisements website with sections devoted to jobs, housing, personals, for sale, items wanted, services, community, gigs, résumés, and discussion forums, while providing micro community news, information and business directory content.

CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com

**

PowerSecure International, Inc. (POWR)

POWR reported that it has been awarded approximately $20 million of new business .

The new business awards include approximately $7 million of new turnkey distributed generation business, approximately $7 million of additional utility infrastructure business and approximately $6 million in new energy efficiency sales.

POWR is a leading provider of utility and energy technologies to electric utilities, and their industrial, institutional and commercial customers.

More about PowerSecure International, Inc. (POWR) at www.powersecure.com .

**

Read Full Disclaimer at www.pennyomega.com/disclaimer